首页 > 最新文献

Clinical & Translational Oncology最新文献

英文 中文
Epidemiologic trends and survival outcomes in patients with primary digestive system lymphoma in the United States. 美国原发性消化系统淋巴瘤患者的流行病学趋势和生存结果。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-06 DOI: 10.1007/s12094-024-03768-y
Jiao Jiang, Jieyu Peng, Shu Huang, Xiaomin Shi, Bei Luo, Jia Xu, Wei Zhang, Lei Shi, Muhan Lü, Xiaowei Tang

Background and aims: Primary digestive system lymphoma (PDSL) is an important entity of extranodal lymphoma, yet updated epidemiologic and survival data are lacking.

Methods: Patients diagnosed with PDSL between 1975 and 2020 were identified from the Surveillance, Epidemiology, and End Results database. Kaplan-Meier analysis estimated survival outcomes. Multivariable Cox regression identified independent risk factors, and nomograms were developed to predict 1-, 3-, and 5-year overall survival (OS) and cancer-specific survival (CSS).

Results: A total of 30,568 patients with PDSL were identified, with 57.9% being male and 80.4% white. The most frequent tumor site was the stomach (48.7%) and diffuse large B-cell lymphoma (DLBCL) was the predominant histologic subtype (45.0%). The overall incidence from 2016 to 2020 was 11.11 per 1,000,000 persons, with a decrease observed in lymphoma rates for the stomach, small intestine, large intestine, and pancreas. Long-term trends showed an initial rise in PDSL incidence, followed by a decline since the 1990s. The median OS across all patients was 103 months, with appendiceal lymphoma showing the highest median OS of 253 months. Factors including diagnosis year, age, sex, race, primary tumor site, histologic subtype, stage, and treatment modalities were significantly associated with OS and CSS. Nomograms achieved C-indices of 0.720 for OS and 0.723 for CSS in the training cohort.

Conclusion: The incidence of PDSL initially increased but has recently declined. Survival for all PDSL patients has improved over time. Nomograms to predict survival for patients with DLBCL exhibited good predictive and discriminating abilities.

背景与目的原发性消化系统淋巴瘤(PDSL)是结节外淋巴瘤的一个重要实体,但目前缺乏最新的流行病学和生存数据:方法:从监测、流行病学和最终结果数据库中找出1975年至2020年间诊断为PDSL的患者。卡普兰-梅耶尔分析估计了生存结果。多变量考克斯回归确定了独立的风险因素,并绘制了预测1年、3年和5年总生存率(OS)和癌症特异性生存率(CSS)的提名图:共发现30568名PDSL患者,其中57.9%为男性,80.4%为白人。最常见的肿瘤部位是胃(48.7%),弥漫大B细胞淋巴瘤(DLBCL)是最主要的组织学亚型(45.0%)。2016 年至 2020 年的总发病率为每 100 万人 11.11 例,胃、小肠、大肠和胰腺的淋巴瘤发病率有所下降。长期趋势显示,PDSL发病率最初有所上升,但自20世纪90年代以来有所下降。所有患者的中位生存期为103个月,其中阑尾淋巴瘤的中位生存期最高,为253个月。诊断年份、年龄、性别、种族、原发肿瘤部位、组织学亚型、分期和治疗方式等因素与OS和CSS显著相关。在训练队列中,OS和CSS的提名图C指数分别为0.720和0.723:结论:PDSL 的发病率最初有所上升,但最近有所下降。随着时间的推移,所有 PDSL 患者的生存率都有所提高。预测DLBCL患者生存期的提名图显示出良好的预测和鉴别能力。
{"title":"Epidemiologic trends and survival outcomes in patients with primary digestive system lymphoma in the United States.","authors":"Jiao Jiang, Jieyu Peng, Shu Huang, Xiaomin Shi, Bei Luo, Jia Xu, Wei Zhang, Lei Shi, Muhan Lü, Xiaowei Tang","doi":"10.1007/s12094-024-03768-y","DOIUrl":"https://doi.org/10.1007/s12094-024-03768-y","url":null,"abstract":"<p><strong>Background and aims: </strong>Primary digestive system lymphoma (PDSL) is an important entity of extranodal lymphoma, yet updated epidemiologic and survival data are lacking.</p><p><strong>Methods: </strong>Patients diagnosed with PDSL between 1975 and 2020 were identified from the Surveillance, Epidemiology, and End Results database. Kaplan-Meier analysis estimated survival outcomes. Multivariable Cox regression identified independent risk factors, and nomograms were developed to predict 1-, 3-, and 5-year overall survival (OS) and cancer-specific survival (CSS).</p><p><strong>Results: </strong>A total of 30,568 patients with PDSL were identified, with 57.9% being male and 80.4% white. The most frequent tumor site was the stomach (48.7%) and diffuse large B-cell lymphoma (DLBCL) was the predominant histologic subtype (45.0%). The overall incidence from 2016 to 2020 was 11.11 per 1,000,000 persons, with a decrease observed in lymphoma rates for the stomach, small intestine, large intestine, and pancreas. Long-term trends showed an initial rise in PDSL incidence, followed by a decline since the 1990s. The median OS across all patients was 103 months, with appendiceal lymphoma showing the highest median OS of 253 months. Factors including diagnosis year, age, sex, race, primary tumor site, histologic subtype, stage, and treatment modalities were significantly associated with OS and CSS. Nomograms achieved C-indices of 0.720 for OS and 0.723 for CSS in the training cohort.</p><p><strong>Conclusion: </strong>The incidence of PDSL initially increased but has recently declined. Survival for all PDSL patients has improved over time. Nomograms to predict survival for patients with DLBCL exhibited good predictive and discriminating abilities.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations. 一项关于非小细胞肺癌和表皮生长因子受体 20 外显子插入突变患者的临床特征、治疗顺序和疗效的真实世界研究。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-05 DOI: 10.1007/s12094-024-03776-y
Guillermo Suay, Paloma Martín-Martorell, Francisco Aparisi, María Arnal, María Guirado, Aitor Azkárate, Javier Garde-Noguera, José David Cumplido-Burón, Amelia Insa, José Francisco González-Muñoz, Sarai Palanca, María Díaz, Alfredo Sánchez-Hernández, Óscar Juan-Vidal

Objectives: EGFR exon 20 insertion (EGFRex20ins) mutations are found in up to 4% of all patients with non-small cell lung cancer (NSCLC). These patients are often insensitive to EGFR-tyrosine kinase inhibitors (TKIs) and have worse prognosis than patients with more common EGFR mutations. In this multicenter, retrospective, real-world study, we sought to determine whether the administration of recently approved treatments that specifically target EGFRex20ins mutations could significantly improve outcomes in this patient population.

Materials and methods: We evaluated the clinical features of 41 patients diagnosed with NSCLC and EGFRex20ins mutations, their evolution, and response to treatments received across 7 hospitals in the Valencian Community, Spain, between 31st December 2012 and 31st December 2022.

Results: 32 patients (72%) developed metastatic disease, and 29 (71%) of them received oncological treatment. We found that administering a targeted therapy against EGFRex20ins mutations (amivantamab, mobocertinib and/or sunvozertinib) at some point during the course of treatment, significantly increased the median OS of metastatic patients from 8 months (95% CI 0-21.7) to 30 months (95% CI 11.1-48.8; Hazard ratio = 0.297, p = 0.02).

Conclusion: Our findings contribute to the evolving standard of care for this specific population and highlight the clinical benefits of targeted cancer therapies.

研究目的在所有非小细胞肺癌(NSCLC)患者中,高达 4% 的患者存在表皮生长因子受体外显子 20 插入(EGFRex20ins)突变。这些患者通常对表皮生长因子受体酪氨酸激酶抑制剂(TKIs)不敏感,预后比表皮生长因子受体更常见突变的患者更差。在这项多中心、回顾性、真实世界研究中,我们试图确定最近批准的专门针对表皮生长因子受体ex20ins突变的治疗是否能显著改善这类患者的预后:我们评估了西班牙巴伦西亚大区 7 家医院在 2012 年 12 月 31 日至 2022 年 12 月 31 日期间确诊为 NSCLC 和 EGFRex20ins 基因突变的 41 例患者的临床特征、病情发展以及对治疗的反应:32名患者(72%)出现转移性疾病,其中29人(71%)接受了肿瘤治疗。我们发现,在治疗过程中的某个阶段使用针对表皮生长因子受体ex20ins突变的靶向疗法(阿米万他单抗、莫伯替尼和/或舒伐他尼),可显著提高转移性患者的中位生存期,从8个月(95% CI 0-21.7)提高到30个月(95% CI 11.1-48.8;危险比=0.297,P=0.02):我们的研究结果为这一特殊人群不断发展的治疗标准做出了贡献,并凸显了癌症靶向疗法的临床优势。
{"title":"A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations.","authors":"Guillermo Suay, Paloma Martín-Martorell, Francisco Aparisi, María Arnal, María Guirado, Aitor Azkárate, Javier Garde-Noguera, José David Cumplido-Burón, Amelia Insa, José Francisco González-Muñoz, Sarai Palanca, María Díaz, Alfredo Sánchez-Hernández, Óscar Juan-Vidal","doi":"10.1007/s12094-024-03776-y","DOIUrl":"https://doi.org/10.1007/s12094-024-03776-y","url":null,"abstract":"<p><strong>Objectives: </strong>EGFR exon 20 insertion (EGFRex20ins) mutations are found in up to 4% of all patients with non-small cell lung cancer (NSCLC). These patients are often insensitive to EGFR-tyrosine kinase inhibitors (TKIs) and have worse prognosis than patients with more common EGFR mutations. In this multicenter, retrospective, real-world study, we sought to determine whether the administration of recently approved treatments that specifically target EGFRex20ins mutations could significantly improve outcomes in this patient population.</p><p><strong>Materials and methods: </strong>We evaluated the clinical features of 41 patients diagnosed with NSCLC and EGFRex20ins mutations, their evolution, and response to treatments received across 7 hospitals in the Valencian Community, Spain, between 31st December 2012 and 31st December 2022.</p><p><strong>Results: </strong>32 patients (72%) developed metastatic disease, and 29 (71%) of them received oncological treatment. We found that administering a targeted therapy against EGFRex20ins mutations (amivantamab, mobocertinib and/or sunvozertinib) at some point during the course of treatment, significantly increased the median OS of metastatic patients from 8 months (95% CI 0-21.7) to 30 months (95% CI 11.1-48.8; Hazard ratio = 0.297, p = 0.02).</p><p><strong>Conclusion: </strong>Our findings contribute to the evolving standard of care for this specific population and highlight the clinical benefits of targeted cancer therapies.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer. 前列腺癌患者使用地加瑞克和 GnRH 激动剂治疗心血管疾病风险的系统回顾和荟萃分析。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-05 DOI: 10.1007/s12094-024-03772-2
Francisco Cezar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, Clara Rocha Dantas, Nathália Hoffmeister, Francinny Alves Kelly, Rommel Mario Rodríguez Burbano

Background: Degarelix is a third-generation GnRH receptor antagonist approved for the treatment of prostate cancer, however, the decision to use a GnRH agonist or an antagonist depends on several factors. We aimed to perform a meta-analysis comparing the cardiovascular disease risk between degarelix and gonadotropin-releasing hormone agonists in patients with all stages of prostate cancer.

Methods: Databases were searched for randomized control trials (RCTs) and observational studies that compared the risk of cardiovascular disease between degarelix and GnRH agonists in patients with prostate cancer. We computed for binary endpoints risk ratio (RR) or hazard ratio (HR) with 95% confidence intervals (CI) which were analyzed using a random-effects model.

Results: A total of 15 studies were included with 123,969 patients and follow-up ranging from 3 to 13 months. Degarelix was associated with a significantly lower incidence of major adverse cardiovascular events (RR 0.59; 95% CI 0.41-0.84; p = 0.003; I2 = 84%). Incidence of stroke (RR 0.89; 95% CI 0.56-1.42; p = 0.62; I2 = 0%), all-cause mortality (RR 0.64; 95% CI 0.37-1.13; p = 0.12; I2 = 41%), hypertension (RR 0.71; 95% CI 0.48, 1.04; p = 0.08; I2 = 0%), myocardial infarction (HR 1.04; 95% CI 0·59-1·84; p = 0·86; I2 = 66%), heart failure (HR 0.79; 95% CI 0.38-1.62; p = 0.52; I2 = 79%) and arrhythmia (RR 0.63; 95% CI 0.28-1.41; p = 0.86; I2 = 37%), did not reach a statistically significant difference between groups.

Conclusion: In patients with prostate cancer, degarelix is associated with a significantly lower incidence of major adverse cardiovascular events.

背景:地加瑞克是第三代促性腺激素释放激素受体拮抗剂,已被批准用于治疗前列腺癌,然而,使用促性腺激素释放激素激动剂还是拮抗剂取决于多种因素。我们的目的是进行一项荟萃分析,比较地加瑞克和促性腺激素释放激素激动剂对各期前列腺癌患者的心血管疾病风险:我们在数据库中搜索了比较地加瑞克和促性腺激素释放激素激动剂在前列腺癌患者中心血管疾病风险的随机对照试验(RCT)和观察性研究。我们计算了二元终点的风险比(RR)或危险比(HR)及95%置信区间(CI),并采用随机效应模型进行分析:结果:共纳入15项研究,患者人数为123969人,随访时间为3至13个月。地加瑞克可显著降低主要不良心血管事件的发生率(RR 0.59;95% CI 0.41-0.84;P = 0.003;I2 = 84%)。中风(RR 0.89;95% CI 0.56-1.42;p = 0.62;I2 = 0%)、全因死亡率(RR 0.64;95% CI 0.37-1.13;p = 0.12;I2 = 41%)、高血压(RR 0.71;95% CI 0.48,1.04;p = 0.08;I2 = 0%)、心肌梗死(HR 1.04;95% CI 0-59-1-84;p = 0-86;I2 = 66%)、心力衰竭(HR 0.79;95% CI 0.38-1.62;p = 0.52;I2 = 79%)和心律失常(RR 0.63;95% CI 0.28-1.41;p = 0.86;I2 = 37%),组间差异无统计学意义:结论:在前列腺癌患者中,地加瑞克可显著降低主要不良心血管事件的发生率。
{"title":"A systematic review and meta-analysis of cardiovascular disease risk with degarelix and GnRH agonists in prostate cancer.","authors":"Francisco Cezar Aquino de Moraes, Vitor Kendi Tsuchiya Sano, Clara Rocha Dantas, Nathália Hoffmeister, Francinny Alves Kelly, Rommel Mario Rodríguez Burbano","doi":"10.1007/s12094-024-03772-2","DOIUrl":"https://doi.org/10.1007/s12094-024-03772-2","url":null,"abstract":"<p><strong>Background: </strong>Degarelix is a third-generation GnRH receptor antagonist approved for the treatment of prostate cancer, however, the decision to use a GnRH agonist or an antagonist depends on several factors. We aimed to perform a meta-analysis comparing the cardiovascular disease risk between degarelix and gonadotropin-releasing hormone agonists in patients with all stages of prostate cancer.</p><p><strong>Methods: </strong>Databases were searched for randomized control trials (RCTs) and observational studies that compared the risk of cardiovascular disease between degarelix and GnRH agonists in patients with prostate cancer. We computed for binary endpoints risk ratio (RR) or hazard ratio (HR) with 95% confidence intervals (CI) which were analyzed using a random-effects model.</p><p><strong>Results: </strong>A total of 15 studies were included with 123,969 patients and follow-up ranging from 3 to 13 months. Degarelix was associated with a significantly lower incidence of major adverse cardiovascular events (RR 0.59; 95% CI 0.41-0.84; p = 0.003; I<sup>2</sup> = 84%). Incidence of stroke (RR 0.89; 95% CI 0.56-1.42; p = 0.62; I<sup>2</sup> = 0%), all-cause mortality (RR 0.64; 95% CI 0.37-1.13; p = 0.12; I<sup>2</sup> = 41%), hypertension (RR 0.71; 95% CI 0.48, 1.04; p = 0.08; I<sup>2</sup> = 0%), myocardial infarction (HR 1.04; 95% CI 0·59-1·84; p = 0·86; I<sup>2</sup> = 66%), heart failure (HR 0.79; 95% CI 0.38-1.62; p = 0.52; I2 = 79%) and arrhythmia (RR 0.63; 95% CI 0.28-1.41; p = 0.86; I<sup>2</sup> = 37%), did not reach a statistically significant difference between groups.</p><p><strong>Conclusion: </strong>In patients with prostate cancer, degarelix is associated with a significantly lower incidence of major adverse cardiovascular events.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Different approach to M descriptor for future staging of oligometastatic disease in SCLC: A cross-sectional survival analysis. 采用不同的 M 描述因子对 SCLC 中的寡转移性疾病进行未来分期:横断面生存分析
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-05 DOI: 10.1007/s12094-024-03778-w
Melahat Uzel Şener, Pınar Akın Kabalak, Suna Kavurgacı, Nilgün Yılmaz Demirci, Derya Kızılgöz, Fazlı Yanık, Sinem Ermin, Yasemin Söyler, Yekta Altemur Karamustafaoğlu, Demet Türkay Pakna, Ahmet Dumanlı, Ülkü Yılmaz

Purpose: This study aimed to investigate the impact of oligometastasis and the M descriptor on survival in small cell lung cancer (SCLC).

Methods: This multicenter, retrospective study included patients with newly diagnosed extensive-stage SCLC(ES-SCLC) from 2010 to 2020. Subgroups: Group 1: single metastasis in a single organ, Group 2: 2-5 metastases in a single organ, Group 3: 6 or more metastases in a single organ, and Group 4: metastases in two or more organs. This classification was based on the 9th Staging-M descriptor. Three-year progression-free survival (PFS) and overall survival (OS) analyses were conducted.

Results: The mean age of the 439 patients was 62 ± 10 years, and 89.5% of them were male. The mean PFS for Groups 1, 2, 3, 4 was 10.7 months (95% CI 8.9-12.5), 7.5 months (95% CI 5.6-9.4), 4.3 months (95% CI 2.9-5.7), and 5.4 months (95% CI 4.7-6.1), respectively. PFS in Group 2 was significantly higher. The mean OS for Groups 1, 2, 3, 4 was 13.3 months (95% CI 11.2-15.3), 9.5 months (95% CI 7.1-11.9), 7.1 months (95% CI 4.5-9.7), and 6.9 months (95% CI 6.0-7.9), respectively. OS in Group 1 was significantly higher. OS and PFS in the M1b group were significantly higher than in the M1c1 and M1c2 groups (p < 0.05) with no statistical difference between the M1c1 and M1c2 groups.

Conclusion: There is no significant difference in survival between the M1c1 and M1c2 groups. In ES-SCLC, the number of metastases may be a more predictive factor for prognosis than the number of metastatic organs.

目的:本研究旨在探讨寡转移和M描述因子对小细胞肺癌(SCLC)生存期的影响:这项多中心回顾性研究纳入了2010年至2020年新诊断的广泛期SCLC(ES-SCLC)患者。分组:第1组:单个器官有转移;第2组:单个器官有2-5个转移;第3组:单个器官有6个或更多转移;第4组:两个或更多器官有转移。这一分类是根据第 9 次分期-M 描述法进行的。进行了三年无进展生存期(PFS)和总生存期(OS)分析:439名患者的平均年龄为(62±10)岁,89.5%为男性。第1、2、3、4组的平均生存期分别为10.7个月(95% CI 8.9-12.5)、7.5个月(95% CI 5.6-9.4)、4.3个月(95% CI 2.9-5.7)和5.4个月(95% CI 4.7-6.1)。第 2 组的 PFS 明显更高。第1、2、3、4组的平均OS分别为13.3个月(95% CI 11.2-15.3)、9.5个月(95% CI 7.1-11.9)、7.1个月(95% CI 4.5-9.7)和6.9个月(95% CI 6.0-7.9)。第一组的 OS 明显更高。M1b组的OS和PFS明显高于M1c1组和M1c2组(P 结论:M1b组的OS和PFS明显高于M1c1组和M1c2组:M1c1组和M1c2组的生存率无明显差异。在 ES-SCLC 中,转移灶的数量可能比转移器官的数量更能预测预后。
{"title":"Different approach to M descriptor for future staging of oligometastatic disease in SCLC: A cross-sectional survival analysis.","authors":"Melahat Uzel Şener, Pınar Akın Kabalak, Suna Kavurgacı, Nilgün Yılmaz Demirci, Derya Kızılgöz, Fazlı Yanık, Sinem Ermin, Yasemin Söyler, Yekta Altemur Karamustafaoğlu, Demet Türkay Pakna, Ahmet Dumanlı, Ülkü Yılmaz","doi":"10.1007/s12094-024-03778-w","DOIUrl":"https://doi.org/10.1007/s12094-024-03778-w","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to investigate the impact of oligometastasis and the M descriptor on survival in small cell lung cancer (SCLC).</p><p><strong>Methods: </strong>This multicenter, retrospective study included patients with newly diagnosed extensive-stage SCLC(ES-SCLC) from 2010 to 2020. Subgroups: Group 1: single metastasis in a single organ, Group 2: 2-5 metastases in a single organ, Group 3: 6 or more metastases in a single organ, and Group 4: metastases in two or more organs. This classification was based on the 9th Staging-M descriptor. Three-year progression-free survival (PFS) and overall survival (OS) analyses were conducted.</p><p><strong>Results: </strong>The mean age of the 439 patients was 62 ± 10 years, and 89.5% of them were male. The mean PFS for Groups 1, 2, 3, 4 was 10.7 months (95% CI 8.9-12.5), 7.5 months (95% CI 5.6-9.4), 4.3 months (95% CI 2.9-5.7), and 5.4 months (95% CI 4.7-6.1), respectively. PFS in Group 2 was significantly higher. The mean OS for Groups 1, 2, 3, 4 was 13.3 months (95% CI 11.2-15.3), 9.5 months (95% CI 7.1-11.9), 7.1 months (95% CI 4.5-9.7), and 6.9 months (95% CI 6.0-7.9), respectively. OS in Group 1 was significantly higher. OS and PFS in the M1b group were significantly higher than in the M1c1 and M1c2 groups (p < 0.05) with no statistical difference between the M1c1 and M1c2 groups.</p><p><strong>Conclusion: </strong>There is no significant difference in survival between the M1c1 and M1c2 groups. In ES-SCLC, the number of metastases may be a more predictive factor for prognosis than the number of metastatic organs.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142577121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Degradation fragments of Tau and type IV collagen as serum biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumab. 用尼伐单抗和贝伐单抗治疗复发性胶质母细胞瘤患者的血清生物标记物Tau和IV型胶原降解片段。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-05 DOI: 10.1007/s12094-024-03775-z
Christina Jensen, Simone Maarup, Hans Skovgaard Poulsen, Benedikte Hasselbalch, Morten Karsdal, Inge Marie Svane, Ulrik Lassen, Nicholas Willumsen

Purpose: There is an unmet need for new treatment options and biomarkers for patients with glioblastoma (GBM). Here we investigated three non-invasive biomarkers: type VI collagen degraded by granzyme B (C4G) and matrix metalloproteases (C4M), respectively, and ADAM10-degraded Tau (Tau-A).

Methods: Biomarker levels in pre- and on-treatment serum samples from patients with recurrent GBM (n = 39) treated with nivolumab and bevacizumab (NCT03890952) were compared to healthy levels (n = 22) and associated with overall survival (OS) outcome (median cutpoint). Longitudinal changes in biomarkers were investigated by a Mixed-effects analysis.

Results: Tau-A (p < 0.0001) and C4G (p = 0.005), but not C4M (p = 0.106), were increased in patients. High Tau-A and C4G associated with improved OS (Tau-A: HR = 0.41, 95%CI = 0.20-0.86, C4G: HR = 0.47, 95%CI = 0.24-0.94). Only C4G increased with treatment (p = 0.024-0.005).

Conclusions: Tau-A and C4G are elevated in serum from patients with recurrent GBM and prognostic for OS. If validated, these biomarkers could be applied to clinical trials.

目的:胶质母细胞瘤(GBM)患者对新的治疗方案和生物标志物的需求尚未得到满足。在此,我们研究了三种非侵入性生物标志物:分别由颗粒酶 B(C4G)和基质金属蛋白酶(C4M)降解的 VI 型胶原,以及 ADAM10 降解的 Tau(Tau-A):将接受尼伐单抗和贝伐单抗(NCT03890952)治疗的复发性GBM患者(39人)治疗前和治疗中血清样本中的生物标志物水平与健康人(22人)的水平进行比较,并将其与总生存期(OS)结果(中位数切点)相关联。通过混合效应分析研究了生物标志物的纵向变化:结果:Tau-A(p复发性 GBM 患者血清中的 Tau-A 和 C4G 升高,是 OS 的预后指标。如果得到验证,这些生物标记物可应用于临床试验。
{"title":"Degradation fragments of Tau and type IV collagen as serum biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumab.","authors":"Christina Jensen, Simone Maarup, Hans Skovgaard Poulsen, Benedikte Hasselbalch, Morten Karsdal, Inge Marie Svane, Ulrik Lassen, Nicholas Willumsen","doi":"10.1007/s12094-024-03775-z","DOIUrl":"https://doi.org/10.1007/s12094-024-03775-z","url":null,"abstract":"<p><strong>Purpose: </strong>There is an unmet need for new treatment options and biomarkers for patients with glioblastoma (GBM). Here we investigated three non-invasive biomarkers: type VI collagen degraded by granzyme B (C4G) and matrix metalloproteases (C4M), respectively, and ADAM10-degraded Tau (Tau-A).</p><p><strong>Methods: </strong>Biomarker levels in pre- and on-treatment serum samples from patients with recurrent GBM (n = 39) treated with nivolumab and bevacizumab (NCT03890952) were compared to healthy levels (n = 22) and associated with overall survival (OS) outcome (median cutpoint). Longitudinal changes in biomarkers were investigated by a Mixed-effects analysis.</p><p><strong>Results: </strong>Tau-A (p < 0.0001) and C4G (p = 0.005), but not C4M (p = 0.106), were increased in patients. High Tau-A and C4G associated with improved OS (Tau-A: HR = 0.41, 95%CI = 0.20-0.86, C4G: HR = 0.47, 95%CI = 0.24-0.94). Only C4G increased with treatment (p = 0.024-0.005).</p><p><strong>Conclusions: </strong>Tau-A and C4G are elevated in serum from patients with recurrent GBM and prognostic for OS. If validated, these biomarkers could be applied to clinical trials.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142584844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Menopausal status-dependent alterations in the transcript levels of genes encoding ERα, ERβ, PR and HER2 in breast tumors with different receptor status. 不同受体状态的乳腺肿瘤中编码 ERα、ERβ、PR 和 HER2 的基因转录本水平的变化与绝经状态有关。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-04 DOI: 10.1007/s12094-024-03777-x
Caglar Berkel

Background: Breast cancer has distinct causes and prognoses in patients with premenopausal and postmenopausal status. The expression status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are analyzed by immunohistochemistry (IHC) to classify molecular subtypes of breast cancer among which large differences in prognosis exist.

Methods: The mRNA expression of ESR1 (encoding ERα), ESR2 (encoding ERβ), PGR (encoding PR), and ERBB2 (encoding HER2) was analyzed based on menopausal status (pre- vs post-menopausal) in tumors from breast cancer patients with different receptor status, in R programming environment, using transcriptomics data from TCGA-BRCA project.

Results: In ER-positive or PR-positive or HER2-negative breast tumors, ESR1 transcript levels were found to be higher in tumors from postmenopausal women than those from premenopausal women; in contrast, ESR2 transcript levels were lower in tumors from postmenopausal women than those from premenopausal women. Furthermore, PGR mRNA expression was lower in breast tumors from postmenopausal women than those from premenopausal women, only in those with ER + or PR + status. The expression of these genes between tumors from pre- and post-menopausal patients with breast cancer was also analyzed based on the combination of status of three receptors.

Conclusion: Together, the results suggest that mRNA expression of ESR1, ESR2, and PGR might differ depending on menopausal status in breast tumors with certain receptor status. More importantly, the change in the expression of ESR1 and ESR2 following menopause is in the opposite directions in breast cancer patients showing the need to identify particular molecular mechanisms regulating the expression of ER isoforms post-menopause in different directions in breast cancer patients, considering the high clinical importance of these receptors in terms of the prognosis of patients with breast cancer.

背景:绝经前和绝经后乳腺癌患者的病因和预后各不相同。通过免疫组化(IHC)分析雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体 2(HER2)的表达状态,对预后存在巨大差异的乳腺癌分子亚型进行分类:方法:利用TCGA-BRCA项目的转录组学数据,在R编程环境下,根据绝经状态(绝经前与绝经后)分析不同受体状态的乳腺癌患者肿瘤中ESR1(编码ERα)、ESR2(编码ERβ)、PGR(编码PR)和ERBB2(编码HER2)的mRNA表达:结果发现:在ER阳性、PR阳性或HER2阴性的乳腺肿瘤中,绝经后女性肿瘤的ESR1转录物水平高于绝经前女性肿瘤;相反,绝经后女性肿瘤的ESR2转录物水平低于绝经前女性肿瘤。此外,绝经后妇女乳腺肿瘤中 PGR mRNA 的表达也低于绝经前妇女,仅在 ER + 或 PR + 状态的肿瘤中表达较高。根据三种受体的组合状态,还分析了绝经前和绝经后乳腺癌患者肿瘤中这些基因的表达情况:总之,研究结果表明,ESR1、ESR2 和 PGR 的 mRNA 表达可能因绝经状态的不同而在具有特定受体状态的乳腺肿瘤中有所不同。更重要的是,ESR1 和 ESR2 在乳腺癌患者绝经后的表达变化方向相反,这表明,考虑到这些受体在乳腺癌患者预后方面的高度临床重要性,有必要确定调节绝经后乳腺癌患者ER 同工酶不同方向表达的特定分子机制。
{"title":"Menopausal status-dependent alterations in the transcript levels of genes encoding ERα, ERβ, PR and HER2 in breast tumors with different receptor status.","authors":"Caglar Berkel","doi":"10.1007/s12094-024-03777-x","DOIUrl":"https://doi.org/10.1007/s12094-024-03777-x","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer has distinct causes and prognoses in patients with premenopausal and postmenopausal status. The expression status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) are analyzed by immunohistochemistry (IHC) to classify molecular subtypes of breast cancer among which large differences in prognosis exist.</p><p><strong>Methods: </strong>The mRNA expression of ESR1 (encoding ERα), ESR2 (encoding ERβ), PGR (encoding PR), and ERBB2 (encoding HER2) was analyzed based on menopausal status (pre- vs post-menopausal) in tumors from breast cancer patients with different receptor status, in R programming environment, using transcriptomics data from TCGA-BRCA project.</p><p><strong>Results: </strong>In ER-positive or PR-positive or HER2-negative breast tumors, ESR1 transcript levels were found to be higher in tumors from postmenopausal women than those from premenopausal women; in contrast, ESR2 transcript levels were lower in tumors from postmenopausal women than those from premenopausal women. Furthermore, PGR mRNA expression was lower in breast tumors from postmenopausal women than those from premenopausal women, only in those with ER + or PR + status. The expression of these genes between tumors from pre- and post-menopausal patients with breast cancer was also analyzed based on the combination of status of three receptors.</p><p><strong>Conclusion: </strong>Together, the results suggest that mRNA expression of ESR1, ESR2, and PGR might differ depending on menopausal status in breast tumors with certain receptor status. More importantly, the change in the expression of ESR1 and ESR2 following menopause is in the opposite directions in breast cancer patients showing the need to identify particular molecular mechanisms regulating the expression of ER isoforms post-menopause in different directions in breast cancer patients, considering the high clinical importance of these receptors in terms of the prognosis of patients with breast cancer.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142570348","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A comprehensive investigation of associations between cell death pathways and molecular and clinical features in pan-cancer. 全面调查泛癌症中细胞死亡途径与分子和临床特征之间的关联。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1007/s12094-024-03769-x
Yin He, Xiaosheng Wang

Background: Regulated cell death (RCD) pathways play significant roles in tumorigenesis. However, systematic investigation into correlations between RCD and various molecular and clinical features, particularly anti-tumor immunity and immunotherapy response in pan-cancer remains lacking.

Methods: Using the single-sample gene set enrichment analysis, we quantified the activities of six RCD pathways (apoptosis, autophagy, ferroptosis, cuproptosis, necroptosis, and pyroptosis) in each cancer specimen. Then, we explored associations of these six RCD pathways with tumor immunity, genomic instability, tumor phenotypes and clinical features, and responses to immunotherapy and targeted therapies in pan-cancer by statistical analyses.

Results: Our results showed that the RCD (except autophagy) activities were oncogenic signatures, as evidenced by their hyperactivation in late stage or metastatic cancer patients, positive correlations with tumor proliferation, stemness, genomic instability and intratumor heterogeneity, and correlation with worse survival outcomes in cancer. In contrast, autophagy was a tumor suppressive signature as its associations with molecular and clinical features in cancer shows an opposite pattern compared to the other RCD pathways. Furthermore, heightened RCD (except cuproptosis) activities were correlated with increased sensitivity to immune checkpoint inhibitors. Additionally, elevated activities of pyroptosis, autophagy, cuproptosis and necroptosis were associated with increased drug sensitivity in a broad spectrum of anti-tumor targeted therapies, while the elevated activity of ferroptosis was correlated with decreased sensitivity to numerous targeted therapies.

Conclusion: RCD (except autophagy) activities correlate with unfavorable cancer prognosis, while the autophagy activity correlate with favorable clinical outcomes. RCD (except cuproptosis) activities are positive biomarkers for anti-tumor immunity and immunotherapy response.

背景:调控细胞死亡(RCD)通路在肿瘤发生中发挥着重要作用。然而,目前仍缺乏对 RCD 与各种分子和临床特征,特别是泛癌症中抗肿瘤免疫和免疫治疗反应之间相关性的系统研究:方法:利用单样本基因组富集分析,我们量化了每份癌症标本中六种 RCD 通路(凋亡、自噬、铁凋亡、杯凋亡、坏死凋亡和热凋亡)的活性。然后,我们通过统计分析探讨了这六种RCD通路与肿瘤免疫、基因组不稳定性、肿瘤表型和临床特征以及泛癌症中对免疫疗法和靶向疗法的反应之间的关联:我们的研究结果表明,RCD(自噬除外)活性是致癌标志,这表现在它们在晚期或转移性癌症患者中的高激活性,与肿瘤增殖、干性、基因组不稳定性和肿瘤内异质性的正相关性,以及与癌症生存结果恶化的相关性。相比之下,自噬是一种肿瘤抑制特征,因为它与癌症的分子和临床特征的关系与其他 RCD 通路的模式相反。此外,RCD(杯突变除外)活性的升高与对免疫检查点抑制剂的敏感性增加有关。此外,热噬、自噬、杯突和坏死活性的升高与多种抗肿瘤靶向疗法药物敏感性的升高有关,而铁噬菌体活性的升高与多种靶向疗法敏感性的降低有关:结论:RCD(自噬除外)活性与不利的癌症预后相关,而自噬活性与有利的临床结果相关。RCD(自噬除外)活性是抗肿瘤免疫和免疫疗法反应的积极生物标志物。
{"title":"A comprehensive investigation of associations between cell death pathways and molecular and clinical features in pan-cancer.","authors":"Yin He, Xiaosheng Wang","doi":"10.1007/s12094-024-03769-x","DOIUrl":"https://doi.org/10.1007/s12094-024-03769-x","url":null,"abstract":"<p><strong>Background: </strong>Regulated cell death (RCD) pathways play significant roles in tumorigenesis. However, systematic investigation into correlations between RCD and various molecular and clinical features, particularly anti-tumor immunity and immunotherapy response in pan-cancer remains lacking.</p><p><strong>Methods: </strong>Using the single-sample gene set enrichment analysis, we quantified the activities of six RCD pathways (apoptosis, autophagy, ferroptosis, cuproptosis, necroptosis, and pyroptosis) in each cancer specimen. Then, we explored associations of these six RCD pathways with tumor immunity, genomic instability, tumor phenotypes and clinical features, and responses to immunotherapy and targeted therapies in pan-cancer by statistical analyses.</p><p><strong>Results: </strong>Our results showed that the RCD (except autophagy) activities were oncogenic signatures, as evidenced by their hyperactivation in late stage or metastatic cancer patients, positive correlations with tumor proliferation, stemness, genomic instability and intratumor heterogeneity, and correlation with worse survival outcomes in cancer. In contrast, autophagy was a tumor suppressive signature as its associations with molecular and clinical features in cancer shows an opposite pattern compared to the other RCD pathways. Furthermore, heightened RCD (except cuproptosis) activities were correlated with increased sensitivity to immune checkpoint inhibitors. Additionally, elevated activities of pyroptosis, autophagy, cuproptosis and necroptosis were associated with increased drug sensitivity in a broad spectrum of anti-tumor targeted therapies, while the elevated activity of ferroptosis was correlated with decreased sensitivity to numerous targeted therapies.</p><p><strong>Conclusion: </strong>RCD (except autophagy) activities correlate with unfavorable cancer prognosis, while the autophagy activity correlate with favorable clinical outcomes. RCD (except cuproptosis) activities are positive biomarkers for anti-tumor immunity and immunotherapy response.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
MRI-based radiogenomics analysis for predicting prognosis and XRCC1 gene polymorphism in pancreatic ductal adenocarcinoma. 基于磁共振成像的放射基因组学分析预测胰腺导管腺癌的预后和XRCC1基因多态性
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-02 DOI: 10.1007/s12094-024-03763-3
Muhammet Göktaş, Derya Karabulut, Ayhan Ünlü, Gkioulsoum Achmet, Nermin Tunçbilek

Purpose: To evaluate the prognostic effects of apparent diffusion coefficient (ADC) values, qualitative MRI findings, and XRCC1 polymorphism in patients with pancreatic ductal adenocarcinoma (PDAC).

Methods: Between January 2019 and December 2021, 41 PDAC patients (23 males; 66.6 ± 8.9 years) diagnosed with MRI and treated with chemotherapy were included in this prospective, unicenter study. Quantitative b:0-800 ADC values were calculated at the workstation using a circular region of interest with a diameter of 2 cm2. Polymerase chain reaction restriction fragment length polymorphism was used to detect XRCC1 genotypes from blood samples. Demographic data, MRI findings, and survival times were recorded. Sensitivity, specificity of ADCmin values, and relationship between XRCC1 genes in predicting survival were calculated and compared.

Results: The median overall survival time was calculated as 9.27 ± 1.4 months. The cut-off value of ADCmin was found to be 0.996 × 10-3 mm2/s for predicting a 4.6-month survival with 77.3% sensitivity and 84.2% specificity. The distribution of XRCC1 codon 399 polymorphism was determined as 26.8% (n = 11) GG, 65.9% (n = 27) AG, and 7.3% (n = 3) AA. There was no statistical correlation between ADCmin values and XRCC1 gene polymorphism (p > 0.05). ADCmin < 0.996 × 10-3 and the XRCC1 codon 399 AG/AA genotype was the subgroup with the worst prognosis (p = 0.035). The mean age at diagnosis was 71.0 ± 9.1 years in cases with GG genotype, while it was 64.6 ± 8.9 years in cases with AG/AA genotype, which was statistically significant (p = 0.038).

Conclusions: ADCmin values are useful for predicting prognosis in patients with PDAC. XRCC1 gene polymorphism may affect the age at diagnosis.

目的:评估表观弥散系数(ADC)值、MRI定性结果和XRCC1多态性对胰腺导管腺癌(PDAC)患者预后的影响:2019年1月至2021年12月期间,41名经MRI诊断并接受化疗的PDAC患者(23名男性;66.6 ± 8.9岁)被纳入了这项前瞻性单中心研究。在工作站上使用直径为 2 平方厘米的圆形感兴趣区计算 b:0-800 ADC 定量值。聚合酶链反应限制性片段长度多态性用于检测血液样本中的 XRCC1 基因型。记录了人口统计学数据、磁共振成像结果和存活时间。计算并比较了ADCmin值的敏感性、特异性以及XRCC1基因在预测生存率方面的关系:中位总生存时间为(9.27 ± 1.4)个月。ADCmin的临界值为0.996 × 10-3 mm2/s,灵敏度为77.3%,特异度为84.2%,可预测4.6个月的生存期。XRCC1密码子399多态性的分布情况为:26.8%(n = 11)GG,65.9%(n = 27)AG,7.3%(n = 3)AA。ADCmin 值与 XRCC1 基因多态性之间没有统计学相关性(P > 0.05)。ADCmin -3和XRCC1密码子399 AG/AA基因型是预后最差的亚组(p = 0.035)。GG基因型病例的平均诊断年龄为(71.0 ± 9.1)岁,而AG/AA基因型病例的平均诊断年龄为(64.6 ± 8.9)岁,差异有统计学意义(p = 0.038):ADCmin值有助于预测PDAC患者的预后。XRCC1基因多态性可能会影响诊断时的年龄。
{"title":"MRI-based radiogenomics analysis for predicting prognosis and XRCC1 gene polymorphism in pancreatic ductal adenocarcinoma.","authors":"Muhammet Göktaş, Derya Karabulut, Ayhan Ünlü, Gkioulsoum Achmet, Nermin Tunçbilek","doi":"10.1007/s12094-024-03763-3","DOIUrl":"https://doi.org/10.1007/s12094-024-03763-3","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the prognostic effects of apparent diffusion coefficient (ADC) values, qualitative MRI findings, and XRCC1 polymorphism in patients with pancreatic ductal adenocarcinoma (PDAC).</p><p><strong>Methods: </strong>Between January 2019 and December 2021, 41 PDAC patients (23 males; 66.6 ± 8.9 years) diagnosed with MRI and treated with chemotherapy were included in this prospective, unicenter study. Quantitative b:0-800 ADC values were calculated at the workstation using a circular region of interest with a diameter of 2 cm<sup>2</sup>. Polymerase chain reaction restriction fragment length polymorphism was used to detect XRCC1 genotypes from blood samples. Demographic data, MRI findings, and survival times were recorded. Sensitivity, specificity of ADCmin values, and relationship between XRCC1 genes in predicting survival were calculated and compared.</p><p><strong>Results: </strong>The median overall survival time was calculated as 9.27 ± 1.4 months. The cut-off value of ADCmin was found to be 0.996 × 10<sup>-3</sup> mm<sup>2</sup>/s for predicting a 4.6-month survival with 77.3% sensitivity and 84.2% specificity. The distribution of XRCC1 codon 399 polymorphism was determined as 26.8% (n = 11) GG, 65.9% (n = 27) AG, and 7.3% (n = 3) AA. There was no statistical correlation between ADCmin values and XRCC1 gene polymorphism (p > 0.05). ADCmin < 0.996 × 10<sup>-3</sup> and the XRCC1 codon 399 AG/AA genotype was the subgroup with the worst prognosis (p = 0.035). The mean age at diagnosis was 71.0 ± 9.1 years in cases with GG genotype, while it was 64.6 ± 8.9 years in cases with AG/AA genotype, which was statistically significant (p = 0.038).</p><p><strong>Conclusions: </strong>ADCmin values are useful for predicting prognosis in patients with PDAC. XRCC1 gene polymorphism may affect the age at diagnosis.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142565049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023). SEOM-GEMCAD-TTD 结肠癌辅助治疗临床指南(2023 年)。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-06-24 DOI: 10.1007/s12094-024-03559-5
Carles Pericay, Clara Montagut, Juan José Reina, Marcos Melian, Julia Alcaide, Noelia Tarazona, Ana Ruiz-Casado, Encarnación González-Flores, Begoña Graña, Cristina Grávalos

Colorectal cancer (CRC) has a 5-year overall survival rate of over 60%. The decrease in the rate of metastatic disease is due to screening programs and the population's awareness of healthy lifestyle. Similarly, advancements in surgical methods and the use of adjuvant chemotherapy have contributed to a decrease in the recurrence of resected disease. Before evaluating a patient's treatment, it is recommended to be discussed in a multidisciplinary tumor board. In stage II tumors, the pathologic characteristics of poor prognosis must be known (T4, number of lymph nodes analyzed less than 12, lymphovascular or perineural invasion, obstruction or perforation, poor histologic grade, presence of tumor budding) and it is mandatory to determine the MSI/MMR status for avoiding administering fluoropyridimidines in monotherapy to patients with MSI-H/dMMR tumors. In stage III tumors, the standard treatment consists of a combination of fluoropyrimidine (oral or intravenous) with oxaliplatin for 6 months although the administration of CAPOX can be considered for 3 months in low-risk tumors. Neoadjuvant treatment is not consolidated yet although immunotherapy is achieving very good preliminary results in MSI-H patients. The use of ctDNA to define the treatment and monitoring of resected tumors is only recommended within studies. These guidelines are intended to help decision-making to offer the best management of patients with non-metastatic colon cancer.

结肠直肠癌(CRC)的 5 年总生存率超过 60%。转移性疾病发生率的下降得益于筛查计划和人们对健康生活方式的认识。同样,手术方法的进步和辅助化疗的使用也降低了切除疾病的复发率。在评估患者的治疗方案之前,建议先由多学科肿瘤委员会进行讨论。对于 II 期肿瘤,必须了解预后不良的病理特征(T4、分析的淋巴结数少于 12 个、淋巴管或神经周围受侵、梗阻或穿孔、组织学分级低、存在肿瘤出芽),而且必须确定 MSI/MMR 状态,以避免对 MSI-H/dMMR 肿瘤患者使用氟啶酰亚胺类药物单药治疗。对于 III 期肿瘤,标准治疗包括氟嘧啶(口服或静脉注射)与奥沙利铂联合治疗 6 个月,但对于低危肿瘤,可考虑使用 CAPOX 治疗 3 个月。尽管免疫疗法在 MSI-H 患者中取得了非常好的初步疗效,但新辅助治疗尚未得到巩固。使用ctDNA确定切除肿瘤的治疗和监测方法仅在研究中被推荐使用。这些指南旨在帮助决策层为非转移性结肠癌患者提供最佳治疗方案。
{"title":"SEOM-GEMCAD-TTD clinical guidelines for the adjuvant treatment of colon cancer (2023).","authors":"Carles Pericay, Clara Montagut, Juan José Reina, Marcos Melian, Julia Alcaide, Noelia Tarazona, Ana Ruiz-Casado, Encarnación González-Flores, Begoña Graña, Cristina Grávalos","doi":"10.1007/s12094-024-03559-5","DOIUrl":"10.1007/s12094-024-03559-5","url":null,"abstract":"<p><p>Colorectal cancer (CRC) has a 5-year overall survival rate of over 60%. The decrease in the rate of metastatic disease is due to screening programs and the population's awareness of healthy lifestyle. Similarly, advancements in surgical methods and the use of adjuvant chemotherapy have contributed to a decrease in the recurrence of resected disease. Before evaluating a patient's treatment, it is recommended to be discussed in a multidisciplinary tumor board. In stage II tumors, the pathologic characteristics of poor prognosis must be known (T4, number of lymph nodes analyzed less than 12, lymphovascular or perineural invasion, obstruction or perforation, poor histologic grade, presence of tumor budding) and it is mandatory to determine the MSI/MMR status for avoiding administering fluoropyridimidines in monotherapy to patients with MSI-H/dMMR tumors. In stage III tumors, the standard treatment consists of a combination of fluoropyrimidine (oral or intravenous) with oxaliplatin for 6 months although the administration of CAPOX can be considered for 3 months in low-risk tumors. Neoadjuvant treatment is not consolidated yet although immunotherapy is achieving very good preliminary results in MSI-H patients. The use of ctDNA to define the treatment and monitoring of resected tumors is only recommended within studies. These guidelines are intended to help decision-making to offer the best management of patients with non-metastatic colon cancer.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11467085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141447439","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
SEOM 2023 clinical guidelines. SEOM 2023 临床指南。
IF 2.8 3区 医学 Q2 ONCOLOGY Pub Date : 2024-11-01 Epub Date: 2024-09-26 DOI: 10.1007/s12094-024-03737-5
Ana Fernández Montes, César Rodríguez
{"title":"SEOM 2023 clinical guidelines.","authors":"Ana Fernández Montes, César Rodríguez","doi":"10.1007/s12094-024-03737-5","DOIUrl":"10.1007/s12094-024-03737-5","url":null,"abstract":"","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":null,"pages":null},"PeriodicalIF":2.8,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142331762","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Clinical & Translational Oncology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1